Cancer Family
Secondary Malignant Neoplasm
CI-CAN-00000346SMNExplore in graph →
4,275 active trials56 approved drugs532 evidence items
- NCIt
- C4968
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000346SMNExplore in graph →
Clinical trials
14,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,961)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00075439 | Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | completed | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00077441 | Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer) | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00079131 |
| Oblimersen in Treating Patients With Merkel Cell Carcinoma |
| completed |
| Phase 2 |
| 37 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Jun 4, 2013 |
| clinicaltrials |
| NCT00084461 | Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00084604 | Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00118183 | Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00397787 | Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00697476 | Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent SCLC | terminated | Phase 1 / Phase 2 | 2 | Armando Santoro, MDOTHER | 1 | May 29, 2013 | clinicaltrials |
| NCT01858207 | Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient | unknown | Phase 2 | 60 | Shi-Ming LinOTHER | 1 | May 23, 2013 | clinicaltrials |
| NCT01830556 | Randomised Phase II, Cetuximab in Combination With 5FU and Cisplatin or Carboplatin Versus Cetuximab in Combination With Paclitaxel and Carboplatin for Treatment of Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck(CETMET) | unknown | Phase 2 | 120 | Karolinska University HospitalOTHER | 2 | May 21, 2013 | clinicaltrials |
| NCT01736878 | Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma(SUMMIT) | withdrawn | Phase 2 | 0 | Eanm Research LtdNETWORK | 1 | May 17, 2013 | clinicaltrials |
| NCT00002470 | Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors | completed | Phase 2 | — | Mid-Atlantic Oncology ProgramOTHER | 1 | May 15, 2013 | clinicaltrials |
| NCT00707889 | Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer | completed | Phase 2 | 159 | AbbVie (prior sponsor, Abbott)INDUSTRY | 14 | May 15, 2013 | clinicaltrials |
| NCT01674374 | Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 0 | May 15, 2013 | clinicaltrials |
| NCT00005812 | Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma | terminated | Phase 2 | 12 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | May 14, 2013 | clinicaltrials |
| NCT00425035 | Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2 | completed | Phase 2 | 115 | AmgenINDUSTRY | 0 | May 13, 2013 | clinicaltrials |
| NCT00363051 | Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy | completed | Phase 2 | 160 | Novartis PharmaceuticalsINDUSTRY | 11 | May 10, 2013 | clinicaltrials |
| NCT00410826 | Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer | completed | Phase 2 | 204 | University of WashingtonOTHER | 1 | May 10, 2013 | clinicaltrials |
| NCT00916669 | A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC) | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 1 | May 8, 2013 | clinicaltrials |
| NCT00242502 | Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery | completed | Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2013 | clinicaltrials |
| NCT00491075 | Pemetrexed Plus Gemcitabine in Renal Cell Cancer | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 24, 2013 | clinicaltrials |
| NCT00003943 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer. | completed | Phase 2 | 3 | Fox Chase Cancer CenterOTHER | 1 | Apr 17, 2013 | clinicaltrials |
| NCT01821482 | A Study of DC-CIK to Treat Hepatocellular Carcinoma | unknown | Phase 2 | 100 | Guangxi Medical UniversityOTHER | 1 | Apr 12, 2013 | clinicaltrials |
| NCT00137774 | Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors | completed | Phase 2 | 34 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 9, 2013 | clinicaltrials |
| NCT01616186 | Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC) | withdrawn | Phase 2 | 0 | Andrea HarzstarkOTHER | 0 | Apr 8, 2013 | clinicaltrials |
| NCT00027872 | Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | completed | Phase 2 | 125 | National Cancer Institute (NCI)NIH | 1 | Mar 25, 2013 | clinicaltrials |
| NCT00182702 | Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Mar 25, 2013 | clinicaltrials |
| NCT00494091 | Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma | completed | Phase 2 | 82 | PfizerINDUSTRY | 3 | Mar 21, 2013 | clinicaltrials |
| NCT00405873 | Study to Evaluate Tumour Response in Cancer Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) With AMT2003 | terminated | Phase 2 | 73 | Auron Healthcare GmbHINDUSTRY | 1 | Mar 20, 2013 | clinicaltrials |
| NCT00951613 | A Study of NK012 in Patients With Relapsed Small Cell Lung Cancer | completed | Phase 2 | 72 | Nippon Kayaku Co., Ltd.INDUSTRY | 1 | Mar 20, 2013 | clinicaltrials |
| NCT00490698 | Zoledronate With Atorvastatin in Renal Cell Carcinoma | completed | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2013 | clinicaltrials |
| NCT01795768 | Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours(FGFR) | unknown | Phase 2 | 48 | Royal Marsden NHS Foundation TrustOTHER | 1 | Mar 15, 2013 | clinicaltrials |
| NCT01811277 | SOX Sequential S-1 in Advanced Biliary Tract Carcinoma（BTC）and Pancreatic Cancer | unknown | Phase 2 | 40 | Peking UniversityOTHER | 1 | Mar 15, 2013 | clinicaltrials |
| NCT00272649 | Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer | completed | Phase 1 / Phase 2 | 22 | Argos TherapeuticsINDUSTRY | 2 | Mar 14, 2013 | clinicaltrials |
| NCT00284154 | Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer | completed | Phase 2 | 51 | SCRI Development Innovations, LLCOTHER | 1 | Mar 13, 2013 | clinicaltrials |
| NCT01333696 | Pemetrexed as Salvage Treatment in Squamous Cell Carcinoma of Head and Neck | unknown | Phase 2 | 32 | Fudan UniversityOTHER | 1 | Mar 5, 2013 | clinicaltrials |
| NCT00429026 | Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation | terminated | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 4, 2013 | clinicaltrials |
| NCT00028028 | CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00029003 | Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00060307 | Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00068783 | S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00087412 | S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer | completed | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00096512 | S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00101114 | Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00126607 | Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00988741 | Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy | completed | Phase 2 | 107 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 5 | Feb 28, 2013 | clinicaltrials |
| NCT00021060 | Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 842 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00033618 | Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck | completed | Phase 2 | 144 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00071994 | Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer) | completed | Phase 2 | 59 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00977561 | A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer | terminated | Phase 2 | 9 | PfizerINDUSTRY | 4 | Feb 25, 2013 | clinicaltrials |
Data updated 24 days agoSource updated Jun 4, 2013source: clinicaltrials